Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of 59.16% is 203% above its 5-year average of -57.27%, near the high end of its 5-year range (-96.73%–61.77%).
As of the fiscal period ended Tuesday, June 30, 2026. 790.66% above its 12-month average of -8.57%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q2 FY2026 (2026-06-30): 59.16%.
RETURN ON EQUITY (ROE)
59.16%
RETURN ON EQUITY (ROE) AVG TTM
-8.57%
RETURN ON EQUITY (ROE) AVG 3Y
-62.13%
RETURN ON EQUITY (ROE) AVG 5Y
-57.27%
RETURN ON EQUITY (ROE) AVG 10Y
-53.69%
RETURN ON EQUITY (ROE) AVG 15Y
-47.72%
RETURN ON EQUITY (ROE) AVG 20Y
-45.32%
CURRENT VS TTM AVG
+790.66%
CURRENT VS 3Y AVG
+195.22%
CURRENT VS 5Y AVG
+203.29%
CURRENT VS 10Y AVG
+210.17%
CURRENT VS 15Y AVG
+223.95%
CURRENT VS 20Y AVG
+230.53%
SECTOR MEDIAN · HEALTHCARE
-41.15%
median of 730 covered companies
CURRENT VS SECTOR MEDIAN
+243.76%
vs the sector median at left
Arbutus Biopharma Corp
Market Cap
$878.06M
Return on Equity (ROE)
59.16%
TTM Avg
-8.57%
3Y Avg
-62.13%
5Y Avg
-57.27%
Market Cap
$898.21M
Return on Equity (ROE)
23.86%
TTM Avg
-5.16%
3Y Avg
-37.28%
5Y Avg
-22.23%
Market Cap
$865.24M
Return on Equity (ROE)
-24.02%
TTM Avg
-108.12%
3Y Avg
-89.93%
5Y Avg
-68.76%
Market Cap
$857.94M
Return on Equity (ROE)
75.67%
TTM Avg
312.76%
3Y Avg
285.83%
5Y Avg
166.15%
Market Cap
$859.52M
Return on Equity (ROE)
-8.03%
TTM Avg
-14.58%
3Y Avg
-29.27%
5Y Avg
-30.82%
Market Cap
$855.16M
Return on Equity (ROE)
-167.25%
TTM Avg
-94.03%
3Y Avg
-58.96%
5Y Avg
-58.96%
Market Cap
$908.51M
Return on Equity (ROE)
N/A
TTM Avg
30.44%
3Y Avg
30.44%
5Y Avg
30.44%
Market Cap
$914.73M
Return on Equity (ROE)
5.94%
TTM Avg
5.38%
3Y Avg
4.71%
5Y Avg
4.13%
Market Cap
$845.02M
Return on Equity (ROE)
-59.07%
TTM Avg
-63.84%
3Y Avg
-29.19%
5Y Avg
-3.25%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Arbutus Biopharma Corp (ABUS) | $878.06M | 59.16% | -8.57% | -62.13% | -57.27% |
| Bioventus Inc. (BVS)vs › | $898.21M | 23.86% | -5.16% | -37.28% | -22.23% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $865.24M | -24.02% | -108.12% | -89.93% | -68.76% |
| Rigel Pharmaceuticals, Inc. (RIGL)vs › | $857.94M | 75.67% | 312.76% | 285.83% | 166.15% |
| SI-BONE, Inc. (SIBN)vs › | $859.52M | -8.03% | -14.58% | -29.27% | -30.82% |
| SL Science Holding Ltd (SLBT)vs › | $855.16M | -167.25% | -94.03% | -58.96% | -58.96% |
| Odyssey Therapeutics, Inc. (ODTX)vs › | $908.51M | N/A | 30.44% | 30.44% | 30.44% |
| HealthStream, Inc. (HSTM)vs › | $914.73M | 5.94% | 5.38% | 4.71% | 4.13% |
| QuidelOrtho Corporation (QDEL)vs › | $845.02M | -59.07% | -63.84% | -29.19% | -3.25% |
| MoonLake Immunotherapeutics (MLTX)vs › | $926.95M | -61.58% | -50.64% | -52.69% | 41.64% |
ROE
59.2%
ROA
55.9%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | 59.16% |
| 2026-03-31 | 61.77% |
| 2025-12-31 | -43.75% |
| 2025-09-30 | -54.62% |
| 2025-06-30 | -65.38% |
| 2025-03-31 | -96.73% |
| 2024-12-31 | -71.81% |
| 2024-09-30 | -71.76% |
| 2024-06-30 | -62.95% |
| 2024-03-31 | -64.89% |
| 2023-12-31 | -68.71% |
| 2023-09-30 | -63.24% |
| 2023-06-30 | -54.15% |
| 2023-03-31 | -48.66% |
| 2022-12-31 | -50.75% |
| 2022-09-30 | -47.31% |
| 2022-06-30 | -45.99% |
| 2022-03-31 | -45.60% |
| 2021-12-31 | -45.00% |
| 2021-09-30 | -55.30% |
| 2021-06-30 | -70.98% |
| 2021-03-31 | -58.05% |
| 2020-12-31 | -62.52% |
| 2020-09-30 | -73.30% |
| 2020-06-30 | -206.23% |
| 2020-03-31 | -197.03% |
| 2019-12-31 | -211.32% |
| 2019-09-30 | -176.14% |
| 2019-06-30 | -54.29% |
| 2019-03-31 | -34.70% |
| 2018-12-31 | -28.50% |
| 2018-09-30 | -34.72% |
| 2018-06-30 | -25.99% |
| 2018-03-31 | -35.80% |
| 2017-12-31 | -46.26% |
| 2017-09-30 | -159.61% |
| 2017-06-30 | -156.54% |
| 2017-03-31 | -204.61% |
| 2016-12-31 | -189.24% |
| 2016-09-30 | -40.98% |
| 2016-06-30 | -41.76% |
| 2016-03-31 | -12.08% |
| 2015-12-31 | -11.16% |
| 2015-09-30 | -11.20% |
| 2015-06-30 | -7.08% |
| 2015-03-31 | -5.53% |
| 2014-12-31 | -44.12% |
| 2014-09-30 | -36.95% |
| 2014-06-30 | -30.98% |
| 2014-03-31 | -27.92% |
| 2013-12-31 | -23.72% |
| 2013-09-30 | 91.09% |
| 2013-06-30 | 86.97% |
| 2013-03-31 | 80.92% |
| 2012-12-31 | 73.44% |
| 2012-06-30 | -237.36% |
| 2012-03-31 | -188.60% |
| 2011-12-31 | -195.50% |
| 2011-09-30 | -145.84% |
| 2011-06-30 | -129.20% |
| 2011-03-31 | -141.33% |
| 2010-12-31 | -115.36% |
| 2010-09-30 | -53.09% |
| 2010-06-30 | -49.60% |
| 2010-03-31 | -35.63% |
| 2009-12-31 | -25.00% |
| 2009-09-30 | -19.60% |
| 2009-06-30 | -28.20% |
| 2009-03-31 | -37.16% |
| 2008-12-31 | -31.11% |
| 2008-09-30 | -22.53% |
| 2008-06-30 | -6.09% |
| 2008-03-31 | -19.51% |
